Semnur Pharmaceuticals, Inc.

Semnur Pharmaceuticals (SMNRW) has recorded zero cyber incidents and zero material red-flag filings in the past 90 days, indicating a quiet operational period in our real-time monitoring window. However, absence of recent events does not establish overall risk profile—biotech firms face structural risks including equity dilution, financing dependency, and R&D execution risk that operate on longer cycles. The full $49 Report extends the analysis back 12 months, calculates dilution pressure scores, maps financing history and runway, and applies AI-driven signals to detect emerging stress patterns missed in short windows. The full $49 Report adds dilution trajectories, 12-month red-flag context, capital structure analysis, and predictive risk scoring to frame what a quiet quarter may obscure.